November 22, 2024 - The pCPA Board of Directors is happy to announce the release of the 2023–24 impact report. This report covers an important timeframe for the pCPA, as we transitioned to a stand-alone organization and introduced a new structure with a CEO and board of directors.
pan-Canadian Pharmaceutical Alliance
Conducting collective expert-informed negotiations for drugs.
Happy holidays from the pCPA
We wish you a joyful holiday season and a happy new year! We look forward to continuing to work together in 2025 to improve health outcomes for Canadians.
What's new at the pCPA
The pan-Canadian Pharmaceutical Alliance (pCPA) is an independent organization whose membership includes the provincial, territorial and federal governments. Member jurisdictions collaborate on a range of public drug plan initiatives to increase and manage access to clinically effective and affordable drug treatments.
One of the pCPA’s key roles is to conduct joint negotiations for brand name and generic drugs in Canada in order to achieve greater value for publicly funded drug programs and patients through its combined negotiating power. Its objectives are to:
- Increase access to clinically relevant and cost-effective treatments
- Achieve consistent and lower drug costs
- Improve consistency in funding decisions
- Reduce duplication and optimize resource utilization
Member jurisdictions
The pCPA member jurisdictions include public drug plans from:
